In this Issue
- ‘Everything’s On the Table’: VA Secretary Signals Openness to Psychedelics, But Concrete Plans Lacking
- Drug Developers Caught Between Tariff Talk, Agency Shake-Ups, and Market Mayhem
- Multi-Lab Preprint Study Challenges Replicability of Psilocybin’s Persistent Effects in Mice
Other Stories - Kwan Lab Links 5-HT2A Receptors and Pyramidal Tract to Psilocybin’s Lasting Effects in Mice
- FDA Clears Nation’s First Whole-Mushroom Psilocybin Study
- Terran vs. Compass Lawsuit Moves Forward as Court Rejects Dismissal
- Other Stories, including: Colorado Regulators Annoint First ‘Healing Center’; Beckley’s Series B?; Celestial Heart Church Receives Formal Recognition from U.S. Government; and more…
***
Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…
Join Pα+ Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue